GENE vs. SRNE, IKT, BCDA, CHRO, ONVO, COEP, TTNP, CELZ, FRTX, and PALI
Should you be buying Genetic Technologies stock or one of its competitors? The main competitors of Genetic Technologies include Sorrento Therapeutics (SRNE), Inhibikase Therapeutics (IKT), BioCardia (BCDA), Chromocell Therapeutics (CHRO), Organovo (ONVO), Coeptis Therapeutics (COEP), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), Fresh Tracks Therapeutics (FRTX), and Palisade Bio (PALI). These companies are all part of the "biological products, except diagnostic" industry.
Genetic Technologies (NASDAQ:GENE) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
In the previous week, Genetic Technologies had 7 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 8 mentions for Genetic Technologies and 1 mentions for Sorrento Therapeutics. Genetic Technologies' average media sentiment score of 0.27 beat Sorrento Therapeutics' score of 0.00 indicating that Genetic Technologies is being referred to more favorably in the media.
0.6% of Genetic Technologies shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 6.5% of Genetic Technologies shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Sorrento Therapeutics received 449 more outperform votes than Genetic Technologies when rated by MarketBeat users. Likewise, 71.10% of users gave Sorrento Therapeutics an outperform vote while only 55.33% of users gave Genetic Technologies an outperform vote.
Genetic Technologies has higher earnings, but lower revenue than Sorrento Therapeutics.
Genetic Technologies has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500.
Summary
Genetic Technologies beats Sorrento Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Genetic Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genetic Technologies Competitors List
Related Companies and Tools
